Suppr超能文献

SNP rs4971059 通过 TRIM46 介导的 HDAC1 降解促进乳腺癌发生和化疗耐药性。

SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation.

机构信息

Department of Biochemistry and Biophysics, School of Basic Medical Sciences, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Health Science Center, Beijing, China.

Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China.

出版信息

EMBO J. 2021 Oct 1;40(19):e107974. doi: 10.15252/embj.2021107974. Epub 2021 Aug 30.

Abstract

Identification of the driving force behind malignant transformation holds the promise to combat the relapse and therapeutic resistance of cancer. We report here that the single nucleotide polymorphism (SNP) rs4971059, one of 65 new breast cancer risk loci identified in a recent genome-wide association study (GWAS), functions as an active enhancer of TRIM46 expression. Recreating the G-to-A polymorphic switch caused by the SNP via CRISPR/Cas9-mediated homologous recombination leads to an overt upregulation of TRIM46. We find that TRIM46 is a ubiquitin ligase that targets histone deacetylase HDAC1 for ubiquitination and degradation and that the TRIM46-HDAC1 axis regulates a panel of genes, including ones critically involved in DNA replication and repair. Consequently, TRIM46 promotes breast cancer cell proliferation and chemoresistance in vitro and accelerates tumor growth in vivo. Moreover, TRIM46 is frequently overexpressed in breast carcinomas, and its expression is correlated with lower HDAC1 expression, higher histological grades, and worse prognosis of the patients. Together, our study links SNP rs4971059 to replication and to breast carcinogenesis and chemoresistance and support the pursuit of TRIM46 as a potential target for breast cancer intervention.

摘要

鉴定恶性转化的驱动力有望对抗癌症的复发和治疗耐药性。我们在此报告,单核苷酸多态性(SNP)rs4971059 是最近全基因组关联研究(GWAS)中鉴定的 65 个新乳腺癌风险基因座之一,作为 TRIM46 表达的活性增强子发挥作用。通过 CRISPR/Cas9 介导的同源重组重现由 SNP 引起的 G 到 A 多态性转换会导致 TRIM46 的明显上调。我们发现 TRIM46 是一种泛素连接酶,可将组蛋白去乙酰化酶 HDAC1 靶向泛素化和降解,并且 TRIM46-HDAC1 轴调节一组基因,包括与 DNA 复制和修复密切相关的基因。因此,TRIM46 促进乳腺癌细胞在体外的增殖和化疗耐药性,并在体内加速肿瘤生长。此外,TRIM46 在乳腺癌中经常过度表达,其表达与较低的 HDAC1 表达、较高的组织学分级和患者预后较差相关。总之,我们的研究将 SNP rs4971059 与复制和乳腺癌发生及化疗耐药性联系起来,并支持将 TRIM46 作为乳腺癌干预的潜在靶点进行研究。

相似文献

引用本文的文献

1
Insights into the DNA damage response and tumor drug resistance.对DNA损伤反应和肿瘤耐药性的见解。
Cancer Biol Med. 2025 Mar 18;22(3):197-204. doi: 10.20892/j.issn.2095-3941.2025.0020.

本文引用的文献

3
TRIM46 Organizes Microtubule Fasciculation in the Axon Initial Segment.TRIM46 组织轴突起始段中的微管束。
J Neurosci. 2019 Jun 19;39(25):4864-4873. doi: 10.1523/JNEUROSCI.3105-18.2019. Epub 2019 Apr 9.
9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验